Europe — EMA

Onpattro (Patisiran)

Patisiran, the active ingredient in Onpattro, is a RNA RNA ? presented as a for use. It treats hereditary transthyretin-mediated amyloidosis in adults.

Patisiran

Request sourcing

Pack/s

What is Patisiran?

Patisiran, the active ingredient in Onpattro, is a RNA RNA ? presented as a for use. It treats hereditary transthyretin-mediated amyloidosis in adults.

GNH USA supplies Onpattro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Patisiran used for?

Onpattro is used in the management of hereditary transthyretin‑mediated amyloidosis, a rare genetic disorder.

- Hereditary transthyretin‑mediated amyloidosis: Improves the outcome by reducing the toxic protein deposits in the nerves and muscle tissues. - ");" "

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →